More News

27 Sep 2021 New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies
23 Sep 2021 AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity
21 Sep 2021 Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
21 Sep 2021 Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
21 Sep 2021 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
21 Sep 2021 Gubra ApS and Bayer AG collaborate to develop next generation cardiorenal treatments
15 Sep 2021 AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
15 Sep 2021 AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
15 Sep 2021 Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
14 Sep 2021 AbbVie and REGENXBIO Announce Eye Care Collaboration
11 Sep 2021 Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology
11 Sep 2021 Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration September 9, 2021
10 Sep 2021 ADARx Raises $75 Million to Advance Growing Pipeline
09 Sep 2021 PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation
09 Sep 2021 ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
09 Sep 2021 Sanofi to acquire Kadmon to further strengthen growth of transplant business
07 Sep 2021 NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease
07 Sep 2021 Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
07 Sep 2021 National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant
03 Sep 2021 Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
02 Sep 2021 Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
31 Aug 2021 Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
30 Aug 2021 Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
26 Aug 2021 NovaRock Biotherapeutics Announces Exclusive License Agreement and Strategic Partnership with Flame BioSciences
25 Aug 2021 Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up